Table 3.

Description of the sickle cell disease cohorts

TraitCSSCD*CSSCD (subset)Brazil
Number of males/ females682 / 593484 / 411162 / 188
Age14.5 ± 12.116.9 ± 11.4n.a.
Follow-up (year)6.5 ± 1.86.7 ± 1.011.4 ± 6.9
Fetal hemoglobin (%)6.4 ± 4.76.1 ± 4.29.2 ± 6.0
Hemoglobin (g/dl)8.6 ± 1.38.5 ± 1.27.5 ± 1.0
Hematocrit (%)24.9 ± 4.124.6 ± 3.723.3 ± 3.0
Red blood cell count ( x 1012/L)2.8 ± 0.62.8 ± 0.62.5 ± 0.6
MCV89.4 ± 9.089.8 ± 8.694.4 ± 9.7
MCH30.1 ± 2.930.2 ± 2.830.5 ± 3.7
White blood cell count ( x 109/L)11.9 ± 2.611.9 ± 2.713.0 ± 4.3
Monocyte (%)7.4 ± 4.57.4 ± 4.38.7 ± 3.1
Platelet count ( x 109/L)442 ± 151448 ± 154412 ± 134
Pain rate (events/patient-year)0.7 ± 1.40.9 ± 1.5n.a.
Acute chest syndrome rate (events/patient-year)0.1 ± 0.30.1 ± 0.2n.a.
Number of deaths453713
Number of participants with renal complication184147n.a.
Number of participants with seizure3130n.a.
  • n.a., not available.

  • *Restricted to the CSSCD participants with DNA available for genotyping.

  • Subset of CSSCD participants used in the analysis of SCD-related complications. See Materials and Methods for selection criteria.

  • Mean ± SD is given.